Revascularization Cuts Mortality, MACE in Coronary CTO

Share this content:
Revascularization Cuts Mortality, MACE in Coronary CTO
Revascularization Cuts Mortality, MACE in Coronary CTO

FRIDAY, Feb. 20, 2015 (HealthDay News) -- For patients with coronary chronic total occlusion (CTO) and well-developed collateral circulation, revascularization is associated with reduced risk of cardiac mortality and major adverse cardiac events (MACE), according to a study published in the Feb. 1 issue of JACC: Cardiovascular Interventions.

Woo Jin Jang, M.D., from Sungkyunkwan University School of Medicine in Seoul, South Korea, and colleagues compared the long-term clinical outcomes of patients with CTO and well-developed collateral circulation. Data were analyzed for 738 patients with Rentrop grade 3 collateral circulation. The incidence of cardiac death and MACE (composite of cardiac death, myocardial infarction, and repeat revascularization) was compared for 502 patients who underwent revascularization and medical therapy versus 236 who underwent medical therapy alone.

The researchers found that the incidence of cardiac death and MACE was significantly lower in the revascularization group versus the medication group (hazard ratios, 0.29 and 0.32; both P < 0.01) during a median follow-up of 42 months. The incidence of cardiac death (hazard ratio, 0.27; P = 0.02) and MACE (hazard ratio, 0.44; P = 0.01) remained significantly lower in the revascularization group versus the medication group, even after propensity score matching.

"In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization may reduce the risk of cardiac mortality and MACE," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »